2019 Deals Review and Deals in China
With the decrease ROI in R & D spending, pharmaceutical companies are trying to grab the market share with Licensing or M&A as much as they can. On the one hand, they become cautious and discerning in transactions; on the other hand, they spend a lot of money on high-quality assets. The market has more uncertainty in 2020 due to the impact of coronavirus. Still, it does not seem to prevent the life science people from moving forward, either to begin clinical trial rapidly or to speed up a large number of mergers and acquisitions. Ms. Zhao Yuwei, from Clarivate, will review the major deals with you in the pharmaceutical field in the past year and will review and comment on the deals of the Chinese market. We believe the 2019 Deals Review and Deals in China will support your business decisions in the future.
Speaker:
Tina Zhao（Life Sciences Solution Consultant, Clarivate）
Organizer:CPhI China
Language: English
Pharmaceutical Packaging and Drug Delivery Device Updates
The conference webcast will invite speakers from multinational pharmaceutical and R&D companies, as well as consulting companies such as Baxter, PharmaSynergy, Tengroth Consulting and IQVIA to interpret the development trend of packaging technology and standards, share new thinking and successful experience in the industry, and comprehensively demonstrate the global development process of pharmaceutical packaging and drug delivery devices.
Speaker:
Luo Hong Yu（Principle scientist of Baxter Healthcare, R&D, China）
Dr. Cheryl Li（CEO & Co-founder, PharmaSynergy）
Yasemin Karanis（IQVIA）
Charbel Tengroth（Tengroth Consulting）
Diana Dai（Global Industry Vertical Manager ，Pharmaceutical Packaging DuPont Tyvek® Healthcare）
Yunxia Zhang Ph.D.（AP Application Development Specialist， DuPont Medical and Pharmaceutical Packaging）
Organizer:InnoPack China, Pharmapack Europe
Language: English
Pharmaceutical Market in China: Policy Reform, Impacts and Opportunities
The policy reform is expected to reshape the pharmaceutical market in China. In this presentation, we shall discuss the followings, but not limited to: •The reform streamlines the clinical trials approval process in China, how would it affect the clinical trial landscape? •What kind of drugs would potentially get expedited review and approval in China? •What pricing and reimbursement strategies were taken by generics manufactures and innovative drug developers under the downward pricing pressure? •What are the incentives for innovation? •How to capture and analysis the opportunities for 505(b)(2) drugs、pediatric drugs、orphan drugs、drugs with breakthrough designation?
Speaker:
Dr. Annie Siu（(PhD, MBA), Principal Analyst, Pharma Intelligence | Informa）
Organizer:CPhI China
Language: English
Best Practices in Pharmaceutical Remote Audits During COVID-19 and Beyond
This presentation will discuss the role that remote auditing has played in pharmaceutical quality during the coronavirus pandemic. It will discuss best practices, and observations from both the supplier and manufacturer point of view. The presentation will also cover the expected role that remote auditing will continue to play post COVID-19.
Speaker:
Jim Fries（CEO, Rx-360）
Organizer:CPhI China
Language: English
How Indian API Register in China
"Drug Registration Management Approach" was newly revised after 13 years on March 30, 2020 to encourage innovation and optimize and improve the efficiency of the drug review. It introduced the new concept and system, updated the registration management, established a link between the review and approval system, and strengthened the concept of whole life cycle of drug management. Our company has been the exclusive agency of more than 80 international API suppliers and collaborated with over 700 domestic production enterprises. Referring to our business model and registration experience, the speech will focus on an overview of the registration and administration of imported APIs, related judicial institutions and laws and regulations, and declaration requirements and review process so as to together explore coping strategies and future industry trends.
Speaker:
Ms. Chengpei Liu（Registration Manager | China Chimopharma）
Organizer:CPhI China
Language: English
Continuous Manufacturing of Drug Products Opportunities and Challenges
One of the innovations in the field of pharmaceutical manufacturing has been continuous manufacturing. The talk will outline the concept, features, potential benefits and control strategies used for continuous manufacturing. Quality/ GMP considerations for implementing continuous manufacturing in the small molecules space along with a key factor- how to bridge existing batch manufacturing with continuous manufacturing, would be addressed. Regulatory and Quality Considerations including a summary of current regulatory environment, relevant regulations and guidelines including industry stand on current guidances would be discussed. Quality/GMP Considerations and Post-approval implementation would also be explored in the talk.
Speaker:
Dr. Deepak Hegde（Senior Vice President-CMC, EOC Pharma）
Organizer:P-MEC China
Language: English
Subscribe to the latest newsletter of Virtual Expo Connect
